Global Crohn’s Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Crohn’s Disease Market Size

• The global crohn’s disease market size was valued at USD 10.21 billion in 2024 and is expected to reach USD 13.65 billion by 2032, at a CAGR of 3.70% during the forecast period
• The market growth is largely fuelled by the increasing prevalence of the disease, advancements in biologic therapies, and rising awareness and diagnosis rates worldwide.
• In addition, supportive regulatory frameworks and improved healthcare infrastructure are enabling wider access to advanced treatment options.

Crohn’s Disease Market Analysis

• The Crohn’s disease market is experiencing steady growth due to advancements in treatment options and increasing patient awareness, leading to better diagnosis and management of the condition
• Innovations in biologic therapies and personalized medicine are enhancing patient outcomes, making the market more dynamic and expanding the range of available treatment solutions
• North America leads the Crohn’s disease market with the largest revenue share in 2024, driven by advanced healthcare infrastructure, rising disease awareness, and widespread adoption of innovative diagnostic and therapeutic options
• Asia-Pacific region is expected to witness the highest growth rate in the global crohn’s disease market, driven by increasing awareness, improving healthcare infrastructure, and growing adoption of advanced diagnostic and treatment options across countries such as China, Japan, and India
• Colonoscopy segment dominates the largest market revenue share in 2024, driven by its critical role in direct visualization and biopsy of the gastrointestinal tract. It remains the gold standard for diagnosis and monitoring of Crohn’s disease, favoured by healthcare providers for its comprehensive assessment capabilities

Report Scope and Crohn’s Disease Market Segmentation    

Crohn’s Disease Market Trends

“Rising Adoption of Biologic Therapies in Crohn’s Disease Management”

• Biologic therapies are increasingly utilized in managing Crohn’s disease due to their targeted approach in modulating the immune response, offering improved efficacy over traditional treatments
• The approval of drugs such as AbbVie's Humira (adalimumab) and Janssen’s Stelara (ustekinumab) has expanded treatment options for patients with moderate to severe Crohn’s disease
  • For instance, in Journal of Crohn's and Colitis (2022) demonstrated that patients treated with Stelara experienced significant reductions in hospitalization and surgery rates over a one-year period compared to those on standard treatments
• In the U.S., the Mayo Clinic has reported improved remission rates among patients who initiate biologic therapy early in their treatment regimen
• The growing body of clinical evidence supporting the effectiveness and safety of biologics is fostering greater confidence among healthcare providers and patients in adopting these therapies

Crohn’s Disease Market Dynamics

Driver

“Increased Prevalence and Awareness of Crohn’s Disease”

• The global prevalence of Crohn’s disease is increasing, mainly due to enhanced diagnostic tools and expanded clinical screening, leading to earlier and more frequent detection
• Public awareness has significantly improved through campaigns and educational efforts
  • For instance, digital platforms and health influencers now actively share information on symptoms such as abdominal pain, weight loss, and chronic diarrhea, encouraging individuals to seek timely diagnoses
• Patient advocacy groups have played a critical role; for instance, the Crohn’s & Colitis Foundation in the U.S. runs awareness initiatives that help destigmatize the condition and promote early intervention
• Pharmaceutical companies are heavily investing in research and development to deliver advanced therapies

Restraint/Challenge

“High Treatment Costs and Limited Accessibility”

• The high cost of biologic therapies poses a significant barrier to Crohn’s disease treatment, particularly in low- and middle-income regions
• These therapies often require long-term use, regular monitoring, and specialist care
  • For instance, anti-TNF biologics such as infliximab demand infusion facilities and follow-up lab testing, adding to the overall treatment cost
• Many patients struggle with affordability due to limited insurance coverage or lack of access to subsidized healthcare
  • For instance, in some parts of Latin America and Southeast Asia, biologic treatment remains financially out of reach for the average patient
• Healthcare infrastructure in under-resourced regions limits access to gastroenterologists and advanced diagnostics, delaying effective treatment

Crohn’s Disease Market Scope

The market is segmented on the basis of procedures, therapeutic type, end user, and distribution channel.

• By Procedures

On the basis of procedures, the Crohn’s disease market is segmented into colonoscopy, flexible sigmoidoscopy, computerized tomography (CT), magnetic resonance imaging (MRI), capsule endoscopy, double-balloon endoscopy, and small bowel imaging. Colonoscopy segment dominates the largest market revenue share in 2024, driven by its critical role in direct visualization and biopsy of the gastrointestinal tract. It remains the gold standard for diagnosis and monitoring of Crohn’s disease, favored by healthcare providers for its comprehensive assessment capabilities.

Flexible sigmoidoscopy is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, due to its minimally invasive procedure and increasing adoption for early detection and monitoring of Crohn’s disease in distal colon regions.

• By Therapeutic Type

On the basis of therapeutic type, the Crohn’s disease market is segmented into non-surgical and surgical treatments. Non-surgical treatment segment holds the largest market share in 2024, led by the increasing use of biologics, immunosuppressants, and corticosteroids for managing mild to moderate cases. The availability of targeted drug therapies has improved patient outcomes and reduced the need for surgical intervention.

Surgical treatments segment is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, due to rising cases of severe Crohn’s disease complications and advancements in less invasive surgical techniques improving patient recovery.

• By End User

On the basis of end user, the Crohn’s disease market is segmented into hospitals and clinics, research institutes, diagnostic centres, and others. Hospitals and clinics segment account for the largest revenue share in 2024, driven by the availability of specialized gastroenterology departments and multidisciplinary care teams.

Research institutes segment is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, due to expanding clinical trials and growing investments in innovative drug development and diagnostic tools.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online, and others. Hospital pharmacies segment dominate the market share as they provide direct access to prescribed medications during patient visits, ensuring compliance and timely treatment.

The online channel segment is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, due to increasing consumer preference for convenient access to medications and growing e-pharmacy adoption.

Crohn’s Disease Market Regional Analysis

• North America leads the Crohn’s disease market with the largest revenue share in 2024, driven by advanced healthcare infrastructure, rising disease awareness, and widespread adoption of innovative diagnostic and therapeutic options
• Patients and healthcare providers in the region benefit from early diagnosis tools and comprehensive treatment programs, including access to biologics and personalized care plans
• The region’s strong focus on research and clinical trials, coupled with favorable reimbursement policies, supports market growth and improved patient outcomes

U.S. Crohn’s Disease Market Insight

The U.S. holds the dominant share within North America, propelled by high disease prevalence and well-established healthcare systems. Increasing investment in biologics and targeted therapies, along with growing patient awareness, drives demand for advanced treatment options. The rise of telehealth and digital patient management platforms enhances access to care, while continuous innovation in diagnostics fosters early disease detection.

Europe Crohn’s Disease Market Insight

The Europe’s market is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, supported by comprehensive healthcare policies and growing emphasis on early diagnosis and treatment adherence. The region experiences increased adoption of cutting-edge therapies and clinical research initiatives. Government programs aimed at improving patient education and disease monitoring also contribute to market expansion across both western and eastern European countries.

U.K. Crohn’s Disease Market Insight

The U.K. market is expected to witness a fastest growth rate during the forecast period of 2025 to 2032 due to rising patient awareness and the integration of advanced treatment protocols within the National Health Service. Increased funding for Crohn’s disease research and growing acceptance of telemedicine services aid in improving disease management. In addition, partnerships between healthcare providers and patient organizations help enhance treatment accessibility and support systems.

Germany Crohn’s Disease Market Insight

The Germany exhibits significant market growth driven by advanced medical research and early disease screening programs. The presence of a strong pharmaceutical industry and focus on personalized medicine foster adoption of novel therapies. The government’s healthcare framework supports patient access to biologics, and rising participation in clinical trials accelerates the availability of innovative treatment options.

Asia-Pacific Crohn’s Disease Market Insight

The Asia-Pacific market is expected to witness a fastest growth rate during the forecast period of 2025 to 2032, fuelled by increasing disease awareness, improving healthcare infrastructure, and expanding insurance coverage in countries such as China, India, and Japan. Urbanization and lifestyle changes contribute to the rising prevalence of Crohn’s disease, while government initiatives promoting healthcare digitization and clinical research further support market expansion.

Japan Crohn’s Disease Market Insight

The Japan’s market is expected to witness a fastest growth rate during the forecast period of 2025 to 2032 by a strong emphasis on early diagnosis and comprehensive treatment, supported by a technologically advanced healthcare system. Increasing elderly population and government-backed health programs drive demand for improved disease management solutions. Integration of digital health tools and IoT devices aids in continuous monitoring and personalized care approaches.

China Crohn’s Disease Market Insight

The China holds a leading position in the Asia-Pacific region due to rapid urbanization, increasing middle-class population, and growing adoption of advanced diagnostic and therapeutic technologies. The government’s focus on expanding healthcare access and investment in research institutions further boost market development. The rise of domestic pharmaceutical companies and growing patient awareness also contribute to the expanding Crohn’s disease treatment landscape.

Crohn’s Disease Market Share

The Crohn’s Disease industry is primarily led by well-established companies, including:

• GSK plc. (U.K.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• Pfizer Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Bristol-Myers Squibb Company (U.S.)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• Janssen Global Services, LLC (U.S.)
• UCB S.A. (Belgium)
• Ferring (Switzerland)
• Tillotts Pharma AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)

Latest Developments in Global Crohn’s Disease Market

• In April 2022, the Crohn’s and Colitis Foundation provided funding to Microbiotica through its Inflammatory Bowel Disease Ventures Program. This investment is intended to accelerate Microbiotica’s research efforts aimed at developing new therapeutic solutions for managing Crohn’s disease and ulcerative colitis. The funding is expected to advance innovative treatment options, potentially improving patient outcomes and expanding the market for inflammatory bowel disease therapies

• In the same month, Engitix expanded its partnership with Takeda to enhance the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel diseases, including Crohn’s disease. This collaboration leverages Engitix’s tissue modeling expertise alongside Takeda’s therapeutic development capabilities, aiming to address significant unmet medical needs. The partnership is poised to drive innovation in treatment strategies, positively impacting the Crohn’s disease market by offering more effective management options

SKU-36286